Catalyst Pharmaceuticals, Inc. (CPRX)
Automate Your Wheel Strategy on CPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including CPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CPRX
- Rev/Share 4.7161
- Book/Share 7.506
- PB 3.1188
- Debt/Equity 0.0027
- CurrentRatio 6.6218
- ROIC 0.2135
- MktCap 2877315328.0
- FreeCF/Share 1.9131
- PFCF 12.2678
- PE 13.1919
- Debt/Assets 0.0023
- DivYield 0
- ROE 0.2639
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CPRX | Robert W. Baird | -- | Outperform | -- | $28 | Feb. 4, 2025 |
News
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Published: February 27, 2025 by: The Motley Fool
Sentiment: Positive
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.
Read More
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Read More
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.
Read More
About Catalyst Pharmaceuticals, Inc. (CPRX)
- IPO Date 2006-11-08
- Website https://www.catalystpharma.com
- Industry Biotechnology
- CEO Richard John Daly
- Employees 181